Description

Through its family of companies, the worlds most comprehensive and

broadly based manufacturer of health care products
Serves the Consumer, Pharmaceutical and Medical Devices and
Diagnostics markets by developing broadly accessible, high quality,
innovative products and services that advance the health and well-being
of people

2013
Investor
Fact Sheet
New Products Introduced
Approximately
in Past 5##%
Years

Approximately

25%

Consistent Performance
30 consecutive years of earnings increases adjusted for special items
51 consecutive years of dividends increases
One Year2

Five Years2

Ten Years2

6.1%
8.2%

2.3%
3.9%

5.5%
8.1%

7.9%
34.6%

7.6%
12.6%

10.8%
8.9%

Sales
Diluted Adjusted Earnings per
Share 1
Dividend Growth
Total Return to Shareholders

1 Non-GAAP, excludes special items. Reconciliation available in corresponding Annual Reports.

2 Compounded Annual Growth Rates

Broadly Based/Exceptional Financial Strength

Over 275 operating companies in 60 countries selling products
throughout the world (approximately 55% of sales outside of U.S.)
Sales split among Consumer, Pharmaceutical and Medical Devices and
Diagnostics business segments
More than 100 drugs marketed; 41 drugs over $50 million; 32 drugs over
$100 million; 8 drugs over $1 billion
One of four U.S. industrial companies that still commands a Triple A
credit rating by both Standard & Poors and Moodys credit rating
agencies
Generated annual free cash flow1 in 2013 of $13.8 billion.
1Non-GAAP

financial measure; defined as operating cash flow less capital spending

Net Earnings(1) (as reported)

$U.S. Millions

$13,831

$12,949

$6,848

2003

2008

(1) Net Earnings attributable to Johnson & Johnson

2013

2013 Worldwide
Sales $71.3 Billion
Worldwide Market Leadership
Largest Medical Device company
7th largest Pharmaceutical company
globally
6th largest Biotech company globally
6th largest Consumer Health Care
company globally
Leadership Positions in Major Markets:
Antithrombotic agents
Antipsychotics (Injectables)
Anti - TNF
Baby Care
Biosurgicals
Blood Glucose Monitoring
Breast Aesthetics
Disposable Contact Lenses
Electrophysiology diagnostics
& catheters
Hormone antagonists
Infection Prevention
Lo-Cal Sweeteners
Minimally Invasive Surgery
Oral Rinses
Orthopaedics
OTC Analgesics
Sanitary Protection
Sutures
Systemic Antipsoriasis
products
Wound Care
Approximately 70% of sales are derived
from products/businesses that have a
#1 or #2 global market share position
Please visit our Home Page on the Internet at
http://www.jnj.com for requests for Company
Reports, including the 2013 Annual Report
and SEC filings. Questions regarding stock
holdings and the Dividend Reinvestment
Plan, should be directed to: Computershare
Trust Company,N.A. Phone (800) 328-9033
21

Johnson & Johnson

Shareholder Return Comparison

S&P 500

$100 Dollars invested December 31, 2003

S&P Pharm

DOLLARS

S&P H/C Equip

230
205
180
155
130
105
80
2003

2005

2007

2009

2011

2013

This chart provides a comparison of cumulative total shareholder return for an

investment in Johnson & Johnson Common Stock as of December 31, 2013 to a similar
investment in the identified indices. Assuming dividends were reinvested, a $100.00
investment in Johnson & Johnson would have grown to $235.59 as of December 31, 2013.
This compares to a value of $204.26 for the S&P 500 Stock Index, $193.25 for the S&P
Pharmaceutical Index and $166.10 for the S&P Healthcare Equipment Index.
Source: Bloomberg

2013 Sales by Geographic

Area
U.S.
$U.S. Billions

2013 Sales by Segment

$U.S. Billions

$31.9

MD&D
Consumer

$28.5

$14.7

45%

40%

21%
26%

19%

Europe

Strong Commitment to New

Product Development
$8.2 billion in Research &
Development expense in 2013
Numerous external alliances and
collaborations entered into
annually
Approximately 25% of products
sold in 2013 introduced in last 5
years
Management Based on a Core Set
of Strategic Principles
Creating Value through Innovation
o Robust pipeline of new and
innovative products
Global Reach/Local Focus
o Broad geographic reach
provides ability to rapidly
introduce new products in
markets around the world
Excellence in Execution
o Maintaining high quality
products and standards
Leading with a Purpose
o Focus on products which
increase access, reduce cost and
improve the quality of health
care

$18.6
39%

10%

Investor Information

$13.4
Asia-Pacific
Africa

$7.4

NYSE Symbol: JNJ

$28.1
Pharmaceutical

Western
Hemisphere

Net Trade Sales

$U.S. Billions

$71.3
International
U.S.

For additional information,

contact:
Investor Relations Department
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
Voice: (800) 950-5089
Fax: (732) 524-3867
Press releases, including earnings
reports, are available via web access:
http://www.jnj.com

$63.7

$41.9

2003

2008

2013

Johnson & Johnson 2013

22